Most viral vaccines are based on inducing neutralizing antibodies (NAbs) against the virus
envelope or spike glycoproteins. Many viral surface proteins exist as trimers that transition …

A subset of individuals infected with HIV-1 develops broadly neutralizing antibodies (bNAbs)
that can prevent infection, but it has not yet been possible to elicit these antibodies by …

A major advance in the search for an HIV vaccine has been the development of a near-
native Envelope trimer (BG505 SOSIP. 664) that can induce robust autologous Tier 2 …

The design of immunogens that elicit broadly reactive neutralizing antibodies (bnAbs) has
been a major obstacle to HIV-1 vaccine development. One approach to assess potential …

Neutralizing antibodies (NAbs) can be both sufficient and necessary for protection against
viral infections, although they sometimes act in concert with cellular immunity. Successful …

The epitopes defined by HIV-1 broadly neutralizing antibodies (bNAbs) are valuable
templates for vaccine design, and studies of the immunological development of these …

Broadly neutralizing monoclonal antibodies protect against infection with HIV-1 in animal
models, suggesting that a vaccine that elicits these antibodies would be protective in …

Encyclopedia of Virology, Fourth Edition, Five Volume Set builds on the solid foundation laid
by the previous editions, expanding its reach with new and timely topics. In five volumes, the …

Eliciting HIV-1-specific broadly neutralizing antibodies (bNAbs) remains a challenge for
vaccine development, and the potential of passively delivered bNAbs for prophylaxis and …

Following the discovery of HIV as a causative agent of AIDS, the expectation was to rapidly
develop a vaccine; but thirty years later, we still do not have a licensed vaccine. Progress …